Emmaus Life Sciences, Inc.
EMMA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $17 | $30 | $18 | $21 |
| % Growth | -43.7% | 60.9% | -10.8% | – |
| Cost of Goods Sold | $1 | $1 | $3 | $3 |
| Gross Profit | $15 | $28 | $16 | $17 |
| % Margin | 92.8% | 95.5% | 85.9% | 83.9% |
| R&D Expenses | $1 | $1 | $2 | $4 |
| G&A Expenses | $11 | $15 | $13 | $13 |
| SG&A Expenses | $17 | $24 | $21 | $19 |
| Sales & Mktg Exp. | $6 | $9 | $7 | $6 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $17 | $25 | $22 | $23 |
| Operating Income | -$2 | $4 | -$7 | -$6 |
| % Margin | -11.4% | 12% | -35.8% | -29.7% |
| Other Income/Exp. Net | -$5 | -$7 | -$4 | -$10 |
| Pre-Tax Income | -$6 | -$4 | -$11 | -$16 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$6 | -$4 | -$11 | -$16 |
| % Margin | -38.7% | -12.6% | -57.8% | -77.4% |
| EPS | -0.1 | -0.07 | -0.21 | -0.32 |
| % Growth | -42.2% | 66.5% | 34.4% | – |
| EPS Diluted | -0.1 | -0.07 | -0.21 | -0.32 |
| Weighted Avg Shares Out | 63 | 53 | 49 | 49 |
| Weighted Avg Shares Out Dil | 63 | 53 | 49 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $1 |
| Interest Expense | $5 | $7 | $5 | $3 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | $4 | -$5 | -$13 |
| % Margin | -5.5% | 12.2% | -29.9% | -61.9% |